Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Kevin_Gorman
|
| gptkbp:collaboratedWith |
gptkb:AbbVie
|
| gptkbp:focusesOn |
neurological diseases
endocrinological diseases |
| gptkbp:foundedBy |
gptkb:Wylie_Vale
Lawrence A. Fritz |
| gptkbp:foundedYear |
1992
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neurocrine Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Ingrezza
Ongentys Orilissa |
| gptkbp:numberOfEmployees |
over 1000
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
drug discovery
drug development |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
NBIX
|
| gptkbp:therapeuticArea |
movement disorders
psychiatric disorders endocrine disorders |
| gptkbp:website |
https://www.neurocrine.com/
|
| gptkbp:bfsParent |
gptkb:Richard_Pops
gptkb:Voyager_Therapeutics gptkb:Sosei_Heptares |
| gptkbp:bfsLayer |
7
|